Newsfeeds - Spark Newswire

3 minute read

FDA
News

Cortexyme Reports GAIN Trial Data; Co Says Data Demonstrated Relationship Between Reduction Of P. gingivalis Infection And Slowing Of Alzheimer’s Disease Progression

Today, 8:04 AM

Cortexyme, Inc. (NASDAQ:CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally

CRTX

5 minute read

51 Biggest Movers From Friday

By Lisa Levin

Today, 8:04 AM

Gainers

2 minute read

Clarus Therapeutics To Present New Real-World Experience Data For JATENZ At 22nd Annual Fall Scientific Meeting Of SMSNA

By Benzinga Newsdesk

Today, 8:04 AM

Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women,

CRTX

1 minute read

Cramer Likes Azek And SoFi, But Said Owning This Stock Could Be Dreadful

By Craig Jones

Today, 8:04 AM

On CNBC's "Mad Money Lightning Round," Jim Cramer said MyMD Pharmaceuticals Inc (NASDAQ: MYMD) is very speculative and one needs to be gutsy to buy it.

AZEK

1 minute read

Canaccord Genuity Maintains Buy on Cortexyme, Raises Price Target to $150

By vishwanath@benzinga.com

Today, 8:04 AM

Canaccord Genuity analyst Sumant Kulkarni maintains Cortexyme (NASDAQ:CRTX) with a Buy and raises the price target from $75 to $150.

CRTX

1 minute read

10 Biggest Price Target Changes For Thursday

By Lisa Levin

Today, 8:04 AM

Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $475 to $625. Intuit rose 0.3% to close at $555.61 on Wednesday.

CRM

1 minute read

HC Wainwright & Co. Maintains Buy on Cortexyme, Raises Price Target to $200

By Benzinga Newsdesk

Today, 8:04 AM

HC Wainwright & Co. analyst Andrew Fein maintains Cortexyme (NASDAQ:CRTX) with a Buy and raises the price target from $76 to $200.

CRTX

2 minute read

Cortexyme Highlights Presentation Of Data Demonstrating Evidence Of P. Gingivalis Infection At Annual Biomarkers For Alzheimer’s Disease Summit

By Bill Haddad

Today, 8:04 AM

GAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer's pathologies Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal

CRTX

3 minute read

Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case

By David Pinsen

Today, 8:04 AM

Screen capture via Cortexyme animation. A Bigger Bubble Than The Late '90s Phoenix Capital Research offered an interesting comparison of the current stock market to that of the dot-com era of the late 1990s in a recent post ("Yes, It's A Bubble and Yes It Will Burst Soon"):

CRTX

3 minute read

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow

By Shanthi Rexaline

Today, 8:04 AM

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.

ABSI